The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor.

[1]  J. Holst,et al.  Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[2]  J. Egan,et al.  GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. , 1998, American journal of physiology. Cell physiology.

[3]  E. Blázquez,et al.  Glucagon-like peptide-1-(7-36)amide increases pulmonary surfactant secretion through a cyclic adenosine 3',5'-monophosphate-dependent protein kinase mechanism in rat type II pneumocytes. , 1998, Endocrinology.

[4]  P. Vergara,et al.  Sympathetic pathways mediate GLP-1 actions in the gastrointestinal tract of the rat , 1998, Regulatory Peptides.

[5]  B. Yeğen,et al.  Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. , 1997, American journal of physiology. Gastrointestinal and liver physiology.

[6]  Yihong Wang,et al.  Novel signal transduction and peptide specificity of glucagon‐like peptide receptor in 3T3‐L1 adipocytes , 1997, Journal of cellular physiology.

[7]  J. Holst,et al.  The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. , 1997, Gut.

[8]  H. Nakabayashi.  Neural monitoring system for circulating somatostatin in the hepatoportal area. , 1997, Nutrition.

[9]  A. Niijima,et al.  The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. , 1996, Journal of the autonomic nervous system.

[10]  E. Blázquez,et al.  Colocalization of Glucagon‐Like Peptide‐1 (GLP‐1) Receptors, Glucose Transporter GLUT‐2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP‐1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake , 1996, Journal of neurochemistry.

[11]  A. Niijima,et al.  Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. , 1996, The American journal of physiology.

[12]  P. J. Larsen,et al.  Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. , 1996, The American journal of physiology.

[13]  J. Habener,et al.  Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. , 1996, Endocrinology.

[14]  I. Valverde,et al.  Glucagon-like peptide-1 binding to rat skeletal muscle , 1995, Peptides.

[15]  B. Göke,et al.  Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. , 1995, Endocrine reviews.

[16]  Katsuji Kobayashi,et al.  Somatostatin receptor on the afferent nerve terminals in the rat hepatoportal area , 1995, Neuroscience Letters.

[17]  B. Göke,et al.  Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9–39) Amide , 1995, Diabetes.

[18]  A. Niijima,et al.  A unique receptor-mediated mechanism in vagal chemoreception of somatostatin in the hepatoportal area. , 1994, Journal of the autonomic nervous system.

[19]  J. Holst,et al.  Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2. , 1994, European journal of pharmacology.

[20]  I. Valverde,et al.  Glucagon‐like peptide 1: A potent glycogenic hormone , 1994, FEBS letters.

[21]  John R. Christiansen,et al.  Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. , 1994, Scandinavian journal of gastroenterology.

[22]  D. Drucker,et al.  Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. , 1994, Endocrinology.

[23]  Shaoping Deng,et al.  Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor , 1993, Diabetes.

[24]  B. Göke,et al.  Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. , 1993, The Journal of biological chemistry.

[25]  M. Wheeler,et al.  Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. , 1993, Endocrinology.

[26]  H. Nakabayashi,et al.  Monoclonal antibodies to somatostatin receptor of rat brain. , 1992, Hybridoma.

[27]  G. Singhg,et al.  Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. , 1992, The Journal of biological chemistry.

[28]  B. Thorens.  Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Raufman,et al.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.

[30]  I I Mansbach CM,et al.  Portal transport of absorbed lipids in rats. , 1991, The American journal of physiology.

[31]  S. Ohashi,et al.  Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. , 1989, Endocrinology.

[32]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[33]  G. Weir,et al.  Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. , 1987, The Journal of clinical investigation.

[34]  J. Holst,et al.  Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut , 1987, FEBS letters.

[35]  A. Niijima,et al.  Somatostatin-sensitive neural system in the liver , 1986, Neuroscience Letters.

[36]  A. Niijima.  AFFERENT IMPULSE DISCHARGES FROM GLUCORECEPTORS IN THE LIVER OF THE GUINEA PIG , 1969, Annals of the New York Academy of Sciences.

[37]  Jie Zhou,et al.  Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations , 1999, Diabetologia.

[38]  S. Bloom,et al.  Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. , 1999, Diabetes.

[39]  G. Greenberg,et al.  Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs. , 1998, Endocrinology.

[40]  F. Clemente,et al.  Inositolphosphoglycans and diacyglycerol are possible mediators in the glycogenic effect of GLP-1(7-36)amide in BC3H-1 myocytes. , 1996, Cell biochemistry and function.

[41]  D. Smith,et al.  Glucagon-like peptide-1 is a physiological incretin in rat. , 1995, The Journal of clinical investigation.

[42]  M D Blaufox,et al.  Blood volume in the rat. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.